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Abstract
Objectives—To assess the criterion validity and responsiveness of Patient Reported Outcomes 
Measurement Information System (PROMIS) in a web-based cohort of children with Crohn’s 
disease.
Study design—We recruited children, ages 9 to 17, with Crohn’s disease and their parents from 
the web-based Crohn’s and Colitis Foundation of America Kids & Teens Study cohort. Upon entry 
into the cohort and 6 months later, children self-reported Crohn’s disease activity, health-related 
quality of life and PROMIS domains of pain interference, anxiety, depression, fatigue and peer 
relationships.
Results—Mean PROMIS scores for the 276 participating patients were worse among those with 
worse self-reported Crohn’s disease activity (per Short Crohn’s disease Activity Index, p<0.005 
for all), Crohn’s disease activity in the prior 6 months (per Manitoba Index, p<0.01 for all) and 
health related quality of life (per IMPACT-35, p<0.001 for all). One hundred forty-three patients 
and their parents completed follow-up questionnaires, 75% of whom reported stable disease 
activity. Those with improved Crohn’s disease activity reported improved PROMIS scores, and 
those with worsened Crohn’s disease activity reported worse PROMIS scores for all domains 
except anxiety. All participants reported improved anxiety from baseline, but those with stable or 
worsened Crohn’s disease activity reported less improvement (p=0.07).
Conclusions—PROMIS scores were significantly associated with known groups of Crohn’s 
disease activity in a linear and clinically meaningful manner, and responded to change in Crohn’s 
disease activity over a 6-month period. This supports the criterion validity and responsiveness of 
pediatric PROMIS.
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Patient-reported outcomes (PROs) are measures of how patients feel and function, obtained 
directly from patients without interpretation, capturing outcomes of importance to patients. 
PROs both complement standard primary outcomes, such as survival or physiologic 
measures, and provide primary outcomes that are necessarily patient-focused, such as patient 
function or quality of life (QoL).(1)
The National Institutes of Health’s Patient Reported Outcomes Measurement Information 
System (PROMIS) is a set of non-disease specific instruments – one for adults and one for 
pediatric patients - assessing domains of physical, psychological, and social health, and 
QoL.(2) PROMIS instruments are unique in that they have been developed using modern 
measurement theory, including rigorous qualitative and quantitative methods.(3) They are not 
disease-specific, and are standardized to a reference population, allowing for comparison 
between different domains of health and across a wide range of chronic diseases.(2), (4) 
Pending additional clinical validation in children with chronic disease, PROMIS pediatric 
measures may serve as endpoints in clinical, observational, comparative effectiveness, and 
health services research.(5, 6) Researchers and clinicians will then be able to use these 
endpoints to identify previously unrecognized psychological, social, or functional health 
disorders, reveal correlations between these disorders and underlying chronic disease 
activity, and prompt appropriate interventions.(7), (8), (9, 10)
When the onset of chronic disease is in childhood or adolescence, it can affect physical, 
psychological, and social development, as well as school performance, resulting in impaired 
or delayed achievement as an adult in interpersonal relationships, education, and 
employment.(11), (12) PROMIS pediatric instruments, which have been developed to assess 
these domains of health in children, have been studied in several disease states, including 
cancer, obesity, asthma, and nephrotic syndrome, and discriminate well among known 
groups of disease activity and severity.(13), (10), (14) However, establishing the validity of 
PROMIS in children requires research in additional chronic diseases.
Children with inflammatory bowel disease (IBD) have been found to have lower quality of 
life and social function than their healthy peers, and experience higher rates of depression 
than children with other chronic diseases.(15), (16) (17), (18) (19) Crohn’s disease has no 
definitive cure and commonly relapses, leading to intermittent disruptions to life and 
wellbeing, affecting a child’s function, development, and QoL; thus, it is an important model 
of a relapsing pediatric chronic disease in which to further evaluate PROMIS.
In this study, we first aimed to evaluate the concurrent criterion validity of PROMIS -how 
PROMIS instrument scores relate to established measures of Crohn’s disease activity and 
health-related QoL- by studying a national, prospective cohort of children with Crohn’s 
disease. Second, we sought to explore the responsiveness of PROMIS instruments to change 
over time amongst cohort members who participated in 6-month follow-up.
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Methods
We performed cross-sectional analyses to evaluate associations between PROMIS measures, 
disease activity indices, disease-specific health-related QoL measures, therapy types, and 
remission status. We also performed exploratory longitudinal analyses to evaluate the 
associations between change in disease activity indices and the same QoL measures. The 
study protocol was reviewed and approved by the Institutional Review Board of the 
University of North Carolina at Chapel Hill.
The Crohn’s and Colitis Foundation of America (CCFA) is a non-profit, volunteer 
organization that funds, publishes, and advocates for IBD research, and provides support for 
patients with IBD of all ages. In 2011, the CCFA sponsored the development and 
maintenance of CCFA Partners, a web-based cohort of over 13,000 adults with self-
identified IBD (ie Crohn’s disease and ulcerative or indeterminate colitis [UC/IC])(20, 21). 
Through a web-based portal, adults in the cohort complete research surveys every six 
months, receive research updates, and access CCFA educational resources.
In 2013, we launched a parallel, web-based cohort of pediatric patients with IBD and their 
parents, the CCFA Partners Kids & Teens Study. The purpose of this cohort is to create a 
long-term community of children with IBD engaged in research focused on the relationships 
between patient-reported exposures, health behaviors, and outcomes.(22) We recruited 
patients with self-reported IBD and their parents via the CCFA by use of their website, email 
rosters, various social media outlets, promotional efforts and word-of-mouth at CCFA 
educational and fundraising events. Patients with at least one participating parent were 
eligible to enter the study. Patients and parents could access the cohort entry portal through 
the study website (www.ccfapartners.org) or through a promotional email link. Enrollment 
began in August of 2013 and remains ongoing. Parents completed the section of survey 
questions regarding the child’s diagnosis of Crohn’s disease, demographic information, and 
family history. Children 9 to 17 years of age completed all symptom-related questions 
themselves, including PROMIS instruments specifically designed for child respondents. Six 
months after entering the cohort, participating patients and parents received email reminders 
to complete follow-up questionnaires of the same disease-related questions and PROMIS 
instruments. For the present analyses, we included all patients age 9 years or older with self-
reported Crohn’s disease who completed all initial surveys, including child-reported 
PROMIS instruments and parent-reported demographic information, by November 2013.
PROMIS
Participating patients completed 4 items (questions), from each of 5 selected PROMIS 
pediatric instruments: anxiety, depression, fatigue, pain interference (a measure of the 
consequences of pain on various aspects of life, including social, cognitive, emotional, 
physical, recreational activities, sleep, and enjoyment of life), and peer relationships (a 
measure of the quality of relationships with friends and other acquaintances).(2) We selected 
these instruments in collaboration with pediatric IBD specialists and experts in PROMIS 
methodology(3), because they measure domains of health and health-related QoL affected by 
Crohn’s disease in children. In an effort to minimize respondent burden and enhance long-
term cohort retention, we chose to use four-item short forms rather than longer forms or 
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computer adaptive testing. Although four-item short forms are less precise at the individual 
level, they can be effective utilized in studies of moderate to large populations such as ours. 
PROMIS instruments are calibrated using a T-score metric with the mean of the original 
calibration population equal to 50, and the standard deviation (SD) in the calibration 
population equal to 10.(2) Minimally Important Differences (MIDs) are the smallest 
differences in PRO scores able to detect a clinically meaningful change in the outcome that 
the PRO is designed to measure. Any differences in PRO scores smaller than the MID are 
likely due to measurement error, rather than a true change in the outcome. Studies in adults 
suggest MIDs for many PROMIS items to be in the range of 2–6.(23) Though MIDs are not 
yet well established in PROMIS pediatric measures, new research utilizing adolescent 
patients, parents, and physicians as judges of clinically important differences in scores, 
suggests MIDs of 2–3 for multiple pediatric PROMIS instruments.(24) Higher scores in any 
PROMIS domain indicate more of the domain being measured – therefore, higher scores for 
anxiety, depression, fatigue, and pain interference indicate poorer wellbeing, whereas higher 
scores for peer relationships indicate better relationships with peers and therefore better 
wellbeing.
Other Variables
We administered the IMPACT-35 questionnaire to assess health-related QOL and we 
measured disease activity the Short Crohn’s Disease Activity Index (SCDAI). Both of these 
indices have been validated and are in wide use in both research and clinical care. A SCDAI 
< 150 indicates clinical remission, and values above this threshold indicate active disease.(25) 
We did not utilize the Pediatric Crohn’s Disease Activity Index(26), (25), which requires 
physical examination and laboratory assessments, and is therefore not feasible for survey 
research. We also assessed IBD activity within the past 6-months via the validated Manitoba 
IBD Index, which is a single-item, patient-reported indicator of IBD activity within the last 
6-months, with scores ranging from one (constantly active) to six (inactive).(27) Additionally, 
we collected information regarding patient demographics, past IBD-related surgery, and both 
past and current IBD medication use -oral 5-aminosalicylates, oral corticosteroids, 
immunomodulators (Methotrexate, Azathioprine and 6-Mercaptopurine), and biologic 
therapies (Infliximab, Adalimumab, Certolizumab Pegol, and Natalizumab). In an effort to 
minimize survey length and respondent burden, we did not question patients about 
conditions or treatments other than IBD, such as depression, anxiety, or other mental health 
diagnoses.
Statistical Analyses
We first performed cross-sectional analyses using descriptive statistics and bivariate 
comparisons to assess the relationships between PROMIS T-scores and patient 
demographics, indices of disease activity (SCDAI), symptom activity within the last six 
months (Manitoba IBD Index) and QoL (IMPACT-35), current medication use, and other 
disease characteristics, including remission status, sex, age, age at diagnosis, time since 
diagnosis, and current steroid use. As disease activity indices and QoL scores were not 
normally distributed, we categorized these values into quartiles. We compared mean 
PROMIS scores between patients in remission and active disease by Pearson’s chi-square 
test. We then compared mean PROMIS scores across quartiles of disease activity and QoL 
Arvanitis et al. Page 4
J Pediatr. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
scores using one-way analysis of variance (ANOVA) and non-parametric tests of trend 
(NPTOT) for the ranks across ordered groups. We investigated possible interactions between 
potential confounders (sex, age, age at diagnosis, time since diagnosis, and current steroid 
use) and PROMIS scores using a likelihood-ratio method. We then used multinomial logistic 
regression to evaluate associations between PROMIS measures and disease activity. After 
fitting models that included all potential confounders, we used a change-in-effect method to 
remove any variable that did not confound the relationship between PROMIS scores and 
disease activity or health-related QoL.(28)
We next performed exploratory longitudinal analyses by grouping patients into categories of 
stable disease, worsening disease, or improving disease, based on a threshold change of 70 
points between baseline and follow-up SCDAI scores.(29) We then compared change in 
mean PROMIS scores across these groups using ANOVA and a NPTOT for the ranks across 
ordered groups. All data were prepared using SAS version 9.3 and analyzed using Stata 
version 13.1.
Results
A total of 276 patients with self-reported Crohn’s disease in children 9 years of age or older 
joined the CCFA Partners Kids & Teens cohort through November 2013. The mean age of 
participating patients was 13 and the mean age at diagnosis was 10 years (Table I); 44% 
were female, and 83% were in remission as determined by SCDAI score (102 ± 71). The 
mean Manitoba IBD Index score was 4, corresponding to occasional disease activity in the 6 
months prior to the survey. Accordingly, only 10% were being treated with oral 
corticosteroids at the time of the survey, 54% were being treated with a biologic, and 47% 
with immunomodulators (Methotrexate, Azathioprine or 6-Mercaptopurine). When asked 
about prior medication use, the majority of patients (87%) reported being treated with oral 
corticosteroids at some point since their diagnosis.
PROMIS Results
Mean baseline PROMIS scores for this cohort are displayed in Table I. Compared with boys, 
girls reported clinically or statistically worse mean PROMIS scores in all domains but peer 
relationships. Older children (age 14–17), compared with younger children (age 9–13 years), 
reported clinically or statistically worse PROMIS scores in all domains except depression 
and pain interference (Table II). Those on current corticosteroid treatment reported clinically 
or statistically worse fatigue, pain interference, and peer relationships, but not anxiety or 
depression (Table II).
Associations with Disease Severity
Mean PROMIS scores for all domains were worse, indicating worse health or more 
dysfunction, among patients with worse reported Crohn’s disease activity, as measured by 
the SCDAI (Table III). Notable, those who reported the best Crohn’s disease activity also 
reported mean PROMIS scores in all domains that were equivalent to or better than that of 
the reference population (Table III). For all PROMIS domains, there was both an overall 
statistically significant difference in mean PROMIS scores amongst the quartiles of disease 
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activity (F <0.001 for all ANOVA), as well as a significant trend of higher PROMIS scores 
across rank-ordered SCDAI quartiles (z <0.001 for all non-parametric tests of trend 
(NPTOT)). Therefore, patients who reported worse Crohn’s disease activity correspondingly 
reported worse anxiety, depression, fatigue, pain interference, and peer relationships. For all 
domains except peer relationships, the differences in PROMIS scores between any two 
disease activity quartiles represented clinically meaningful differences, based on the 
proposed pediatric MID range of two to three. These same statistically significant and 
clinically meaningful differences in scores for all PROMIS domains were maintained when 
patients were grouped by remission status, as determined by reported SCDAI score (Table 
VI; available at www.jpeds.com).
Analogous to the findings across SCDAI quartiles, PROMIS scores for all domains of health 
were worse among patients who reported more active disease in the prior 6 months, as 
measured by the Manitoba IBD Index (Table IV; available at www.jpeds.com). For all 
domains, there was both an overall statistically significant difference in mean PROMIS 
scores amongst the 6 categories (F ≤0.01 for all ANOVA), as well as a trend of higher 
PROMIS scores across rank-ordered Manitoba IBD Index categories (z ≤0.001 for all 
NPTOT). The differences in PROMIS scores between any two Manitoba IBD Index 
categories, for all domains except peer relationships, represented clinically meaningful 
differences (Table IV).
Despite potential differences in disease activity based on sex, age, age at diagnosis, time 
since diagnosis, and current steroid therapy (Table II), we did not find any independent 
effect of these patient characteristics on the relationship between PROMIS scores and 
disease activity using multinomial logistic regression and change-in-effect methods (data not 
shown).
Associations with Health Related QoL
Mean PROMIS scores for all domains were worse among patients reporting worse pediatric 
health related QoL, as measured by the IMPACT-35 (Table V; available at www.jpeds.com). 
For all domains, there was both an overall statistically significant difference in mean 
PROMIS scores between the quartiles (F <0.001 for all ANOVA), as well as a trend of 
higher PROMIS scores across rank-ordered quartiles of QoL (z <0.001 for NPTOT). As with 
the differences in PROMIS scores across SCDAI and Manitoba IBD Index groups, the 
differences in PROMIS scores between any two IMPACT-35 quartiles were not only 
statistically significant, but also represented clinically meaningful differences for all 
domains except peer relationships.
Longitudinal Evaluation of PROMIS Measures
Of the 143 patients who completed six-month follow-up questionnaires, 11% reported 
worsened, 76% stable, and 13% improved Crohn’s disease activity from baseline, based on 
change in SCDAI score. The patients who reported improved Crohn’s disease activity from 
baseline also reported meaningfully improved anxiety, depression, fatigue, pain interference, 
and peer relationships, with improvement in mean PROMIS scores ranging from 4–11 
(Figure and Table VII; available at www.jpeds.com). Similarly, patients who reported 
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worsened Crohn’s disease activity from baseline also reported meaningfully worse PROMIS 
scores in all domains (Figure and Table VII). Patients with stable Crohn’s disease activity 
reported little to no change in PROMIS scores, as demonstrated by a change in PROMIS 
scores of 0–1 compared with baseline (Figure and Table VII). For all domains, the changes 
in PROMIS scores across groups of patients by change in disease activity were also 
statistically significant and linear (Table VII).
Discussion
In this study, we described a cross-sectional and longitudinal evaluation of PROMIS in a 
pediatric population with Crohn’s disease. We found that mean PROMIS scores were 
significantly associated with known groups of Crohn’s disease activity and health-related 
QoL, in a predictable, linear and clinically meaningful manner, thus supporting the 
concurrent criterion validity of PROMIS in our study population. We also observed that 
patients with well-controlled Crohn’s disease reported better PROMIS scores in the domains 
of psychological and physical functioning than the reference population, suggesting that 
with adequate disease control, children with Crohn’s disease lead normal, healthy lives. In 
our exploratory longitudinal analyses, we found that changes in mean PROMIS scores were 
also significantly associated with change reported Crohn’s disease activity over a 6-month 
period, in a predictable, linear and clinically meaningful manner, demonstrating the 
responsiveness of PROMIS in this cohort.
Although baseline scores for all PROMIS domains of health varied significantly and linearly 
across rank-ordered groups of Crohn’s disease severity and health-related QoL, associations 
with peer relationships were less dramatic than for other domains. This pattern is consistent 
with our clinical experience, as well as PROMIS pediatric studies in other chronic disease 
settings where peer relationships are less affected by disease severity than other 
domains.(14),(30),(7) Although incremental changes in Crohn’s disease activity and health-
related QoL are associated with differences in patient-reported anxiety, depression, fatigue, 
and pain interference, peer relationships tend to remain intact except in those whose Crohn’s 
disease is very active or QoL very impaired.
Measuring QoL, physical function, psychological, and social health in a valid, reliable, and 
patient-centered way is centrally important to understanding chronic disease in children and 
improving their care. When adolescents with IBD and their physicians have been surveyed 
about what factors most affect their QoL, there was almost no correlation between 
adolescent and physician reports.(31) Given these disparate viewpoints, it is unlikely that 
physicians and researchers can capture what is important to patients regarding QoL and 
disease control without high-quality PROs. If appropriately captured, PROs of depression 
and other health domains have been shown to independently predict chronic disease activity, 
including in IBD.(32) In addition, PROs can also help identify barriers to remission and 
treatment adherence. In IBD, for example, the subset of patients who continue to have 
impaired health-related QoL despite documented mucosal healing are those with 
significantly more fatigue, anxiety, and depression.(33) In addition, those patients IBD with 
elevated anxiety and depressive symptoms have significantly lower treatment adherence.(34) 
Interventions for anxiety or depressive symptoms are known to be as effective in patients 
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with chronic disease, including IBD, as in the general population, yet remain 
underused.(35),(36),(37)
We sought to validate PROMIS instruments in a pediatric population with Crohn’s disease 
by surveying patients in our CCFA Kids & Teens cohort - a large, geographically diverse 
study population, which allowed for longitudinal assessments of PROMIS instruments. The 
fact that our cohort is a volunteer, internet-based cohort, potentially limits its 
generalizability. In another internet-based cohort of patients with psoriasis, participants 
reported that their disease was less of a burden, despite being more extensive, and were 
significantly better-informed regarding psoriasis therapies compared with 
nonparticipants.(38) Therefore, we may suspect that our population is better informed and 
less likely to consider their disease a burden than the general population with Crohn’s 
disease. Another potential limitation of our study is that a patient’s Crohn’s disease status 
was identified by self-report, rather than review of medical records. However, in our 
validation study of the adult CCFA Partners cohort, self-reported IBD status was confirmed 
by medical records in 96% of participants, suggesting that patients who are involved in the 
CCFA are reliable reporters of their diagnoses. In order to minimize respondent burden and 
improve retention in the Kids & Teens Study cohort, we did not assess comorbid diagnoses 
of anxiety, depression, or other mental health disorders and did not collect data on non-IBD 
medication use. However, such data are not needed to assess criterion validity and explore 
longitudinal responsiveness of PROMIS. Another potential limitation of our study is a 
feature of PROMIS pediatric instruments themselves. Unlike PROMIS adult instruments, 
which are standardized to a general population, PROMIS pediatric T-scores are currently 
standardized to a population that includes a higher proportion of children with chronic 
disease.(39) Although this did not affect our conclusions, it did not allow us to compare our 
study cohort with the general population.
This study supports the criterion validity and responsiveness of child-reported PROMIS 
instruments in Crohn’s disease, adding to our understanding of how PROMIS functions in a 
pediatric population with a relapsing chronic disease. With this basis, important patient-
centered research can proceed, including studies of how incorporating PROMIS in the 
clinical care of children with chronic diseases effects the recognition and treatment of 
psychological, social, and functional burdens of chronic disease, and ultimately, patient 
wellbeing.
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Figure 1. 
a. “Improved” patients reported a 70-point improvement in SCDAI score from baseline to 
time of 6-month follow-up, “Worsened” reported as 70-point worsening in SCDAI score 
from baseline
b. Higher T-score score indicates worse anxiety, depression, fatigue, pain interference, and 
better peer relationships
c. Secondary/Right-sided axis for peer relationships scores only
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Table 1
Characteristics of the Study Population
n = 276
Demographics Age, mean (SD) 13.2 (2.4)
Sex, % female 43.8
Race
 White
 African-American
 Hispanic
 Asian
 Multiracials
90.6
4.1
6.9
0.3
5.0
Highest parental education
 12th grade
 Some college
 College
 Graduate school
2.8
13.2
37.6
46.4
Disease Characteristics % In remission 82.9
Age at diagnosis, mean (SD) 9.8 (3.0)
Therapy Historical therapy, %
 5-Aminosalicylates
 Immunomodulators
 Biologics
 Corticosteroids
 Surgery
63.4
74.6
61.2
86.6
16.7
Current therapy, %
 5-Aminosalicylates
 Immunomodulators
 Biologics
 Corticosteroids
27.9
47.1
54.0
9.8
Disease-Specific Measures Disease-Specific Activity Scores, mean (SD)SCDAIa 102 (71)
Health Related Quality of Live Scores, mean (SD) IMPACT-35b 131 (22)
Disease Activity within the last 6 months, mean (SD) Manitobac 4 (2)
PROMIS measures PROMIS T-scores, mean (SD)
 Anxiety
 Depression
 Fatigue
 Pain interference
 Peer relationships
47 (11)
43 (8)
48 (12)
48 (11)
49 (9)
a3-item questionnaire of Crohn’s disease activity, score < 150 indicates remission
b35-item, self-administered questionnaire of health-related QoL in children with IBD, scores range 35 (poor) to 175 (best)
c1-item questionnaire of IBD activity within the prior 6 months. A score of 4 indicates “occasional” activity
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